secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001628280-25-014541
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife appoints Cathy Coste to board as director and audit committee chair
---------------------------------------------------------------------------

- Effective March 18, 2025, Catherine Coste appointed to board, replacing Joydeep Goswami as audit committee chair.
- Coste brings over 30 years at Deloitte as senior partner and life sciences industry leader.
- She will serve until 2025 Annual Meeting and receive standard non-employee director compensation.
- Board expanded to seven members; Coste independent under SEC and Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828025014541/0001628280-25-014541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828025014541/blfs-20250318.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-014541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer